InvestorsHub Logo
Followers 10
Posts 529
Boards Moderated 0
Alias Born 12/15/2011

Re: angel38 post# 37927

Wednesday, 12/21/2016 12:22:11 PM

Wednesday, December 21, 2016 12:22:11 PM

Post# of 38376

Great to see a PR for ENTB and optimism that 2017 should be the year for canine and feline cancer therapies. IMO, I believe from years of prior testing they know that the therapy works in animals.

From 12/21/16 ENTB PR:
The Company is currently working on codifying its plans and activities in a new website that should be up shortly so everyone can track its progress." Further stated Dr. Koos, "I believe 2017 should be a year we see great progress in bringing new small molecule therapies for animals within reach." .

Its been stated previously that they plan on funding Regen from a revenue stream from ENTB. Give that the speed to market is far greater for animal drugs 2017 is possible. Personally I would not be opposed to a buyout of ENTB to accomplish that revenue goal. Regen has worked with Eli Lilly on NR2F6 and Eli Lilly has a pet division(Elanco). Time will tell.

I would like to see further communication from Koos on ENTB similar to what Lander does for Regen. Lets hope.

GL. IMO.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.